Book Value per Share: cyclotherapeutics.com (CYTH)

Graphic logo of CTD Holdings (CYTH)

Cyclo Therapeutics maintains pricing power due to the uniqueness of Trappsol Cyclo in treating Niemann-Pick disease. Its status as an expert in neurodegenerative pathologies strengthens brand trust. The net asset value per share demonstrates fundamental stability, with the value fixed at -0.47. Independence from macroeconomic factors makes the company a reliable defensive asset within its own product cycle.

CTD Holdings - CYTH Net Assets per Share (period 07/04/2022 - 04/05/2025)

Summary analytical data breakdowns for cyclotherapeutics.com (CYTH)

- price and consensus price forecast:
Stock Quotes CTD Holdings|CYTH - Analyst Forecast Prices
- market capitalization data:
Market Capitalization Cyclo Therapeutics, Inc.|CYTH - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Cyclo Therapeutics|CYTH - Book Valuation of Business|Market Value to Book Value Ratio cyclotherapeutics.com|CYTH - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Cyclo Therapeutics|CYTH - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cyclo Therapeutics, Inc.|CYTH - Company Total Debt|Debts to Book Capitalization Cyclo Therapeutics, Inc.
Analysis of all company metrics:CTD Holdings CYTH
Finished products of cyclotherapeutics.com

Bioethical compliance and the environmental optimization of Cyclo Therapeutics laboratories directly impact the capital expenditure structure and the net asset value. The current value of -0.47 reflects the remaining equity per share in a hypothetical liquidation, which allows for an assessment of the business's fundamental margin of safety via the summary book value per share according to the Benjamin Graham methodology.

Competitors of Cyclo Therapeutics (CYTH)

Accounting Value per Share Vertex Pharmaceuticals Inc. VRTX|ALNY - Book Price of a Share|Book Value per Share Insmed Incorporated INSM|UTHR (unither.com) - Accounting Value of a Share|BMRN: Net Assets per Single Share|Net Assets per Share BBIO|BGM - Net Assets per Single Share|Share Book Value Cogent Corp (COGT)|XERS: Book Value per Share|Net Asset Value per Share kerostx.com KROS|ARCT: Book Value per Share|ETON - Accounting Value per Share|Kamada Corp - Book Value per Share|Fulcrum Corp (FULC) - Net Assets per Share|ABEO (Abeona Therapeutics, Inc.) - Book Value per Share|Book Value per Share MREO|Net Assets per Single Share Protalix BioTherapeutics, Inc. (PLX)|Net Assets per Single Share pliantrx.com (PLRX)|Book Value per Share APLT|RNTX - Net Assets per Share|Accounting Value per Share Gelteq Limited Inc|AYTU - Share Book Value|Book Value per Share CMMB|SRx Health Solutions (SRXH) - Net Asset Value per Share|Book Value per Share Polyrizon Limited (PLRZ)|Equity per Share Zentaris (AEZS)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share